DK2514418T3 - Traditionelt kinesisk lægemiddel omfattende danshen ekstrakter og sanqi ekstrakter og anvendelse deraf - Google Patents

Traditionelt kinesisk lægemiddel omfattende danshen ekstrakter og sanqi ekstrakter og anvendelse deraf Download PDF

Info

Publication number
DK2514418T3
DK2514418T3 DK10837056.0T DK10837056T DK2514418T3 DK 2514418 T3 DK2514418 T3 DK 2514418T3 DK 10837056 T DK10837056 T DK 10837056T DK 2514418 T3 DK2514418 T3 DK 2514418T3
Authority
DK
Denmark
Prior art keywords
group
traditional chinese
chinese drug
danshensu
drug composition
Prior art date
Application number
DK10837056.0T
Other languages
English (en)
Inventor
Jingyan Han
Jun Guo
Jiying Yang
Yu Zhang
Mingxia Wang
Yuying Liu
Original Assignee
Tasly Pharmaceutical Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasly Pharmaceutical Group Co filed Critical Tasly Pharmaceutical Group Co
Application granted granted Critical
Publication of DK2514418T3 publication Critical patent/DK2514418T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (10)

1. Traditionel kinesisk lægemiddelsammensætning bestående af Danshensu og Notoginsenoside R1 i et vægtforhold på (2-6):(0,5-2).
2. Traditionel kinesisk lægemiddelsammensætning ifølge krav 1, hvor den traditionelle kinesiske lægemiddelsammensætning består af Danshensu og Noto-ginsenoside R1 i et vægtforhold på (1-4):1.
3. Traditionel kinesisk lægemiddelsammensætning ifølge krav 2, hvor den traditionel kinesiske lægemiddelsammensætning består af Danshensu og Notoginsenoside R1 i et vægtforhold på 4:1.
4. Farmaceutisk sammensætning omfattende den traditionelle kinesiske lægemiddelsammensætning ifølge ethvert af kravene 1-3 som en aktiv bestanddel, hvor den farmaceutiske sammensætning omfatter 0,1-99,9 vægt-% af den aktive bestanddel, og resten er en eller flere farmaceutisk acceptable bærere.
5. Farmaceutisk sammensætning ifølge krav 4, hvor den farmaceutiske sammensætning er tabletter, kapsler, pastiller, granulat, orale opløsninger, pulvere, pastaer, pellets, piller, suppositorier, tørt pulver inhalationer, aerosoler, geler, injektioner eller lyofiliserede pulvere til injektion; fortrinsvis er tabletterne oralt desintegrerende tabletter eller brusetabletter, de nævnte kapsler er bløde kapsler.
6. Anvendelse af den traditionelle kinesiske lægemiddelsammensætning ifølge ethvert af kravene 1-3 og den farmaceutiske sammensætning ifølge krav 4 eller 5 i fremstillingen af et lægemiddel til bedring af mikrocirkulationsforstyrrelser af hjertet forårsaget af iskæmi/reperfusion.
7. Anvendelse af den traditionelle kinesiske lægemiddelsammensætning ifølge ethvert af kravene 1-3 og den farmaceutiske sammensætning ifølge krav 4 eller 5 i fremstillingen af et lægemiddel til behandling af myokardiebeskadigelse og/eller myokardieinfarkt forårsaget af iskæmi/reperfusion.
8. Anvendelse af den traditionelle kinesiske lægemiddelsammensætning ifølge ethvert af kravene 1-3 og den farmaceutiske sammensætning ifølge krav 4 eller 5 i fremstillingen af et lægemiddel til behandling af myokardiebeskadigelse.
9. Anvendelse af den traditionelle kinesiske lægemiddelsammensætning ifølge krav 7 i fremstillingen af et lægemiddel til hæmning af mikrocirkulationsforstyrrelser med albuminlækage.
10. Anvendelse af den traditionelle kinesiske lægemiddelsammensætning ifølge krav 7 i fremstillingen af et lægemiddel til hæmning af albuminlækage fra venoler.
DK10837056.0T 2009-12-17 2010-12-17 Traditionelt kinesisk lægemiddel omfattende danshen ekstrakter og sanqi ekstrakter og anvendelse deraf DK2514418T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910244837XA CN102100739B (zh) 2009-12-17 2009-12-17 一种含有丹参素和三七皂苷r1的中药组合物及其应用
PCT/CN2010/079928 WO2011072619A1 (zh) 2009-12-17 2010-12-17 一种含有丹参提取物和三七提取物的中药组合物及其应用

Publications (1)

Publication Number Publication Date
DK2514418T3 true DK2514418T3 (da) 2017-02-13

Family

ID=44153939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10837056.0T DK2514418T3 (da) 2009-12-17 2010-12-17 Traditionelt kinesisk lægemiddel omfattende danshen ekstrakter og sanqi ekstrakter og anvendelse deraf

Country Status (11)

Country Link
US (1) US9034398B2 (da)
EP (1) EP2514418B1 (da)
JP (1) JP5701897B2 (da)
KR (1) KR20120101701A (da)
CN (1) CN102100739B (da)
AU (1) AU2010333525B2 (da)
CA (1) CA2782967C (da)
DK (1) DK2514418T3 (da)
EA (1) EA023625B1 (da)
MY (1) MY160218A (da)
WO (1) WO2011072619A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102100739B (zh) 2009-12-17 2013-12-25 天士力制药集团股份有限公司 一种含有丹参素和三七皂苷r1的中药组合物及其应用
CN104147028A (zh) * 2013-05-14 2014-11-19 天士力制药集团股份有限公司 三七皂苷r1对心脏的保护作用
CN111358834B (zh) * 2020-03-20 2022-04-05 南京昌润生物科技有限公司 用于改善微循环及降血脂的二十八烷醇组合物及应用
US20230111558A1 (en) * 2021-10-11 2023-04-13 21St Century Herbs & Health Composition for Preventing and Treating Heart Dysfunction and its Application Thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486464B2 (en) 2000-12-22 2013-07-16 Tasly Pharmaceutical Group Co. Ltd. Herbal composition for angina pectoris, method to prepare same and uses thereof
CN1470255A (zh) * 2002-07-22 2004-01-28 王智民 自丹参三七中提取的制备物及其复方制备方法和医疗用途
CN1200916C (zh) 2002-11-13 2005-05-11 吉林省中医中药研究院 三七叶中总皂苷和黄酮提取物的制备方法
US20050037094A1 (en) * 2003-07-31 2005-02-17 Xijun Yan Composition for heart disease, its active ingredients, method to prepare same and uses thereof
CN100450501C (zh) * 2004-03-17 2009-01-14 天津天士力制药股份有限公司 一种治疗心脑血管疾病的中药制剂及其制备方法
CN1732964A (zh) * 2004-07-03 2006-02-15 山东绿叶天然药物研究开发有限公司 一种药物组合物及其制备方法和用途
CN101006984B (zh) * 2007-02-01 2010-05-19 北京本草天源药物研究院 一种丹参丹酚酸a、三七提取物的注射制剂及其制备方法和应用
CN101244123A (zh) * 2008-02-25 2008-08-20 药都制药集团股份有限公司 三七丹参含片制备新工艺
CN101574391B (zh) * 2008-05-05 2012-08-29 天士力制药集团股份有限公司 丹参总酚酸和三七总皂苷的配伍对微循环障碍引发的疾病的预防和治疗
CN102048720A (zh) 2009-11-05 2011-05-11 天津天士力制药股份有限公司 丹参素、三七皂苷r1,及其配伍对微循环障碍引发的疾病的预防和治疗
CN102100739B (zh) 2009-12-17 2013-12-25 天士力制药集团股份有限公司 一种含有丹参素和三七皂苷r1的中药组合物及其应用

Also Published As

Publication number Publication date
WO2011072619A1 (zh) 2011-06-23
EP2514418B1 (en) 2016-11-02
KR20120101701A (ko) 2012-09-14
JP5701897B2 (ja) 2015-04-15
EP2514418A1 (en) 2012-10-24
JP2013514283A (ja) 2013-04-25
US9034398B2 (en) 2015-05-19
AU2010333525B2 (en) 2013-08-15
CA2782967A1 (en) 2011-06-23
EA201200754A1 (ru) 2012-12-28
CN102100739A (zh) 2011-06-22
EP2514418A4 (en) 2013-10-23
US20120251634A1 (en) 2012-10-04
CA2782967C (en) 2017-06-27
MY160218A (en) 2017-02-28
AU2010333525A1 (en) 2012-06-21
CN102100739B (zh) 2013-12-25
EA023625B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
ES2469490T3 (es) Composición que comprende Salvia miltiorrhiza, Ginseng, Borneol, para el tratamiento de enfermedades cardiacas y cerebrovasculares
AU2014289766B2 (en) Traditional chinese medicine composition, and preparation and application thereof
AU2014289763B2 (en) Traditional chinese medicine composition, and preparation and application thereof
EP2995308B1 (en) Antihypoxic pharmaceutical composition and application thereof
WO2009003356A1 (fr) Composition pharmaceutique pour diminuer l'aire d'un infarctus du myocarde et application de celle-ci
DK2514418T3 (da) Traditionelt kinesisk lægemiddel omfattende danshen ekstrakter og sanqi ekstrakter og anvendelse deraf
WO2014180239A1 (zh) 一种治疗重症高原病的药物组合物
AU2017394430B2 (en) Panax plant extract and pharmaceutical composition and use thereof
EP4144357A1 (en) Traditional chinese medicine composition, and application of preparation of traditional chinese medicine composition in preparing medicine for preventing and/or treating coronavirus disease 2019
CN100508962C (zh) 贝壳杉烷类化合物在制备药物中的应用
WO2016131321A1 (zh) Nadph在制备治疗心脑血管疾病的药物中的应用
CN1679698A (zh) 一种由三七、川芎制成的治疗心脑血管疾病的药物制剂及其制备方法
CN110101693A (zh) 丹酚酸c在制备保护缺血脑组织损伤药物中的应用
CN101574391B (zh) 丹参总酚酸和三七总皂苷的配伍对微循环障碍引发的疾病的预防和治疗
WO2009135423A1 (zh) 治疗心脑血管疾病的药物组合物及其制备方法和药盒
WO2016131320A1 (zh) Nadph在制备治疗心脏疾病药物中的应用
JP6162954B2 (ja) 微小循環障害に起因する疾患を予防及び治療するための医薬の調製におけるダンシェンス、ノトギンセノシドｒ１又はそれらの組み合わせの使用
CN101176772B (zh) 一种由蒲黄与红花制成的药物组合物
CN101773546A (zh) 丹参有效成分同步定位释药微丸及其制备方法
CN101574383A (zh) 三七总皂苷对微循环障碍引发的疾病的预防和治疗
WO2008154794A1 (fr) Utilisation d'extrait de salvia miltiorrhiza pour la préparation d'un médicament pour le traitement de la septicémie
KR20070023755A (ko) 의약 제품에서의 카우렌 화합물의 이용
KR20040072153A (ko) 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물
CN1686470A (zh) 一种治疗心脑血管疾病的中药制剂及其制备方法
CN103381201A (zh) 何首乌提取物在制备抗血栓药品、保健品中的应用